Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
ML41253 trial: what clinicians have said so far
A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
- NCT04321330 ↗
- Completed
- Hoffmann-La Roche
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on ML41253 (atezolizumab in previously-treated advanced thymic carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ML41253 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Carcinoma, Thymic
- Interventions
- Atezolizumab
- Arms
- Atezolizumab · Experimental
- Enrollment
- 34
- Primary outcomes
- Objective response rate (ORR)
- Sponsor
- Hoffmann-La Roche
- Start
- Aug 7, 2020
- Primary completion
- Jul 16, 2023
- Results posted
- No
- Registry record
- NCT04321330 · updated Jun 11, 2024
Publications
linked from the registry- Remon J, Girard N, Novello S, de Castro J, Bigay-Game L, Bernabe R, Greillier L, Mosquera J, Cousin S, Juan O, Sampayo M, Besse B. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clin Lung Cancer. 2022 May;23(3):e243-e246. doi: 10.1016/j.cllc.2021.07.008. Epub 2021 Jul 20. PubMed 34393061